Advisornet Financial’s Sage Therapeutics SAGE Stock Holding History

Advisornet Financial’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-375	Closed	-$2.04K	–	2237
2024 Q4	$2.04K	Hold	375	–	–	﹤0.01%	1617
2024 Q3	$2.71K	Buy	+375	New	+$3.43K	﹤0.01%	1700
2024 Q1	–	Sell	-2	Closed	-$43	–	2442
2023 Q4	$43	Sell	2 -3	-60%	-$59	﹤0.01%	2402
2023 Q3	$103	Sell	5 -1	-17%	-$29	﹤0.01%	2210
2023 Q2	$282	Buy	6 +1	+20%	+$50	﹤0.01%	2160
2023 Q1	$210	Buy	5 +1	+25%	+$43	﹤0.01%	2245
2022 Q4	$153	Buy	+4	New	+$153	﹤0.01%	2239
2021 Q4	–	Sell	-310	Closed	-$14K	–	2130
2021 Q3	$14K	Sell	310 -18	-5%	-$825	﹤0.01%	1367
2021 Q2	$19K	Buy	328 +18	+6%	+$1.27K	﹤0.01%	1245
2021 Q1	$23K	Sell	310 -90	-23%	-$7.38K	﹤0.01%	1158
2020 Q4	$35K	Buy	+400	New	+$29.5K	﹤0.01%	978
2020 Q1	–	Sell	-160	Closed	-$12K	–	1909
2019 Q4	$12K	Buy	+160	New	+$19.7K	﹤0.01%	1350

Other funds holding SAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Advisornet Financial's SAGE Position: Q1 2025 in Review

Advisornet Financial sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 375 shares — an estimated $2.04K sold.

Advisornet Financial first reported a position in SAGE in Q4 2019 and held it in 12 quarters. The position peaked at $35K in Q4 2020. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

Advisornet Financial reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
Advisornet Financial sold 375 Sage Therapeutics shares in Q1 2025, an estimated $2.04K.
Advisornet Financial first reported a position in Sage Therapeutics in Q4 2019 and held it in 12 quarters.
Advisornet Financial's Sage Therapeutics position peaked at $35K in Q4 2020.
198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Advisornet Financial's 13F filing for Q1 2025, filed 7 Apr 2025.